|
Apr 11
|
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
|
|
Apr 8
|
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
|
|
Feb 11
|
Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study
|
|
Jan 11
|
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
|
|
Dec 27
|
Algernon Pharmaceuticals Announces Closing of Private Placement
|
|
Dec 27
|
Algernon Pharmaceuticals Announces Increase to Private Placement
|
|
Nov 30
|
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD
|
|
Aug 8
|
Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study
|